Tag: NASDAQ:AGIO

  • Biotech Gainers: Fate Therapeutics (NASDAQ:FATE), Celsus Therapeutics PLC (NASDAQ:CLTX), Agios Pharmaceuticals (NASDAQ:AGIO), Sangamo Biosciences (NASDAQ:SGMO)

    Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced  the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. Fate Therapeutics Inc. (NASDAQ:FATE) stock opened at $8.80 in last session, and closed at $9.47, while the day range of Fate Therapeutics Inc. (NASDAQ:FATE) stock is $8.32 – $10.00. The stock showed a positive weekly performance of 33.38%.

    Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) is a biopharmaceutical company. The Company is focused on the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) stock opened at $6.20 in last session, and closed at $6.60 by gaining 6.62%. The 52 week range of $5.76 – $25.00. Company’s market capitalization is $26.53 million.

    Agios Pharmaceuticals (NASDAQ:AGIO) released its earnings data on Thursday. The company reported ($0.40) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.34) by $0.06, Analyst Ratings Network.com reports. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.19 million. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock increased 26.20% and finished the last session at $39.93. The EPS of the stock remained -11.57. Company’s market capitalization is $908.21 million.

    Sangamo Biosciences Inc. (NASDAQ:SGMO) announced after the bell Wednesday that the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans was published in the New England Journal of Medicine. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened the session at $22.98, and closed the session at $22.96. The 52 week range of the Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock remained $6.86 – $24.12 and the day range was $21.76 – $24.12.